BottleTreat APAP Overdose ASAP

 

 

 

Shorter I.V. Treatment Regimen for APAP Overdose

Available by Prescription Only
HCPCS code J0132 (Please refer to your coding department for complete billing information.)

 

Acetaminophen

Involved in 133,530 poisoning exposures in 2004, acetaminophen is the leading cause of toxic drug ingestions in the United States1. These can lead to hepatic toxicity and death when ingested in quantities of 150 mg/kg or more2. It is currently found in over 600 Rx and OTC products3.

“Intravenous administration, therefore, has advantages when compared with oral NAC administration during the initial dosing period due to the absence of emesis and rapid treatment.”
-Rocky Mountain Poison and Drug Center

Acetadote®

Acetadote®, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury.

21v72

Accuracy

  • Accurate I.V. dosing - not affected by level of consciousness

Reduced Treatment Time

  • Short, 21-hour I.V. infusion vs. 72-hour, 8-dose oral regimen

Convenience

  • No nausea or vomiting due to taste and smell
  • Dosing information now available for patients under 40 kg

 

Important Risk Information

Acetadote® is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously.

Acetadote® should be used with caution in patients with asthma, or where there is a history of bronchospasm. The total volume administered should be adjusted for patients less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of 5% dextrose should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure, and death.

View full prescribing information Adobe Acrobat file

  1. Watson, et al. 2004 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. 2005;23(5):589-666.
  2. Acetadote package insert
  3. FDA launches consumer campaign on safe use of OTC pain products [press release]. Rockville, MD: US Food and Drug Administration; January 22, 2004.